Crawford & Company increases share repurchase program by 2 million shares

ATLANTA - Crawford & Company (NYSE:CRD-A and CRD-B), a global provider of claims management and outsourcing solutions, announced Thursday that its Board of Directors has authorized an increase to the company’s share repurchase program by an additional 2 million shares of common stock.

The board also extended the termination date of the program to December 31, 2027, from the previously established share repurchase program initiated on November 4, 2021, and expanded on February 10, 2022.

Under the original program, Crawford was authorized to repurchase up to 7 million shares of its common stock, with 634,920 shares remaining available for repurchase as of October 30, 2025. InvestingPro data shows management has been aggressively buying back shares, one of several bullish indicators identified in their analysis.

"Given our solid revenue growth, progress against our strategy and our current share price, which we believe is trading below intrinsic value, we are pleased with our Board’s authorization of an additional two million shares for repurchase," said Rohit Verma, Crawford chief executive officer, in a press release statement. The company has demonstrated revenue growth of 4.48% over the last twelve months, with total revenue reaching $6.79 billion.

The company noted that repurchases may be made in the open market or through privately negotiated transactions at management’s discretion, subject to applicable regulatory guidelines. The authorization does not obligate Crawford to acquire any stock, and purchases may be commenced or suspended based on market conditions and other factors.

Additionally, the Board declared a quarterly dividend of $0.075 per share on both Class A and Class B Common Stock, payable on December 5, 2025, to shareholders of record as of November 19, 2025. The company currently offers a dividend yield of 0.68% and has maintained dividend payments for 14 consecutive years according to InvestingPro data.

Crawford & Company, based in Atlanta, serves clients in more than 70 countries, offering two classes of stock that are substantially identical except for voting rights for Class B Common Stock and protections for the non-voting Class A Common Stock.

In other recent news, Agilent Technologies announced the appointment of Adam S. Elinoff as its new chief financial officer, effective November 17. Elinoff brings extensive experience from his 19-year tenure at Amgen, where he held various leadership roles, including regional CFO for multiple regions. Rothschild Redburn initiated coverage on Agilent with a Buy rating and set a price target of $165, citing the company’s diversified business structure. Additionally, UBS upgraded Agilent’s stock rating from Neutral to Buy, raising the price target to $170, highlighting the company’s potential for growth leadership and recent instrument launches.

Agilent has also introduced a new line of high-performance liquid chromatography (HPLC) columns aimed at biotherapeutics applications, featuring proprietary Ultra Inert technology for improved chromatographic performance. Furthermore, Agilent declared a quarterly dividend of 24.8 cents per share, payable on October 22, 2025, to shareholders of record as of September 30, 2025. The company noted that future dividend decisions will be subject to board approval. These developments reflect Agilent’s ongoing efforts to strengthen its leadership and product offerings in the laboratory technologies sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.